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224 ABSTRACT
25 Psychiatric disorders are highly heritable and associated with a wide variety of social 
26 adversity and physical health problems. Using genetic liability (rather than phenotypic 
27 measures of disease) as a proxy for psychiatric disease risk can be a useful alternative 
28 for research questions that would traditionally require large cohort studies with long-
29 term follow up. 
30 Here we conducted a hypothesis-free phenome-wide association study in about 
31 300,000 participants from the UK Biobank to examine associations of polygenic risk 
32 scores (PRS) for five psychiatric disorders (major depression (MDD), bipolar disorder 
33 (BP), schizophrenia (SCZ), attention-deficit/ hyperactivity disorder (ADHD) and autism 
34 spectrum disorder (ASD)) with 23,004 outcomes in UK Biobank, using the open-
35 source PHESANT software package.
36 There was evidence after multiple testing (p<2.55x10-06) for associations of PRSs with 
37 226 outcomes, most of them attributed to associations of PRSMDD (n=120) with mental 
38 health factors and PRSADHD (n=77) with socio-demographic factors. Among others, we 
39 found strong evidence of associations between a 1 standard deviation increase in 
40 PRSADHD with 1.1 months younger age at first sexual intercourse [95% confidence 
41 interval [CI]: -1.26,-0.94]; PRSASD with 0.01% reduced lower erythrocyte distribution 
42 width [95%CI: -0.013,-0.007]; PRSSCZ with 0.98 odds of playing computer games 
43 [95%CI:0.976,0.989]; PRSMDD with a 0.11 points higher neuroticism score 
44 [95%CI:0.094,0.118]  and PRSBP with 1.04 higher odds of having a university degree 
45 [95%CI:1.033,1.048].
46 We were able to show that genetic liabilities for five major psychiatric disorders 
47 associate with long-term aspects of adult life, including socio-demographic factors, 
48 mental and physical health. This is evident even in individuals from the general 
49 population who do not necessarily present with a psychiatric disorder diagnosis.
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350 AUTHOR SUMMARY
51 Psychiatric disorders are associated with a wide range of adverse health, social and 
52 economic problems. Our study investigates the association of genetic risk for five 
53 common psychiatric disorders with socio-demographics, lifestyle and health of about 
54 330,000 participants in the UK Biobank using a systematic, hypothesis-free approach. 
55 We found that genetic risk for attention deficit/hyperactivity disorder (ADHD) and 
56 bipolar disorder were most strongly associated with lifestyle factors, such as time of 
57 first sexual intercourse and educational attainment. Genetic risks for autism spectrum 
58 disorder and schizophrenia were associated with altered blood cell counts and time 
59 playing computer games, respectively. Increased genetic risk for depression was 
60 associated with other mental health outcomes such as neuroticism and irritability. In 
61 general, our results suggest that genetic risk for psychiatric disorders associates with 
62 a range of health and lifestyle traits that were measured in adulthood, in individuals 
63 from the general population who do not necessarily present with a psychiatric disorder 
64 diagnosis. However, it is important to note that these associations aren’t necessary 
65 causal but can themselves be influenced by other factors, like socio-economic factors 
66 and selection into the cohort. The findings inform future hypotheses to be tested using 
67 causally informative designs.
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468 INTRODUCTION
69 Family and twin research as well as large-scale genome-wide association studies 
70 (GWAS) have shown that psychiatric disorders are highly heritable (1) and that genetic 
71 risks for psychiatric disorders also are associated with socio-economic factors, 
72 physical health outcomes as well as other psychiatric disorders (2-5). Using genetic 
73 liability (rather than phenotypic measures of disease) as a proxy for psychiatric 
74 disease risk can be a useful alternative for research questions that would traditionally 
75 require long-term follow up and big datasets due to the low prevalence of some of the 
76 psychiatric disorders of interest in the population (e.g. adult-onset health 
77 consequences of child neurodevelopmental disorders). In addition, while high genetic 
78 risk for a psychiatric disorder is not always indicative of a diagnosis of psychiatric 
79 disease, it can index underlying subthreshold symptomatology that can still impact 
80 later adversities and quality of life (6).
81 So far, studies have used hypothesis-driven approaches to investigate associations of 
82 genetic risk for psychiatric disorders with various psychiatric and health outcomes as 
83 well as lifestyle factors (7, 8). However, big data resources that are readily available, 
84 such as UK Biobank with about 500,000 participants, provide rich phenotypic 
85 information that can be used for hypothesis-free studies and offset the multiple testing 
86 burden. Phenome scans are a type of hypothesis-free analysis where the association 
87 of a trait of interest is systematically tested with a potentially large number of 
88 phenotypes and can be hypothesis-generating by identifying an association when 
89 there is no prior reason to expect that an association may exist. As all available 
90 phenotypes are tested and the less ‘significant’ results published alongside those of 
91 greater ‘significance’, phenome scans can help to reduce biases associated with 
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592 hypothesis-driven studies where researchers might only publish the most desirable or 
93 expected results. 
94 In a Mendelian randomization phenome-wide association study (MR-pheWAS) 
95 genetic risk is used as a proxy for lifelong liability for a disorder to explore associations 
96 of this genetic liability with traits that may evolve as a consequence. Understanding 
97 these associations will be essential to inform prevention or early intervention 
98 strategies. However, conclusions about causality are limited due to the low predictive 
99 power and high pleiotropic effects of genetic risk scores for psychiatric conditions (8).
100 The aim of this study was to investigate the associations between genetic risk for five 
101 common psychiatric disorders – attention-deficit/ hyperactivity disorder (ADHD), 
102 autism spectrum disorder (ASD), schizophrenia (SCZ), major depression (MDD) and 
103 bipolar disorder (BP) - with a wide range of socio-demographic, lifestyle, physical and 
104 mental health outcomes in UK Biobank, using the systematic hypothesis-free MR-
105 pheWAS approach.
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6106 RESULTS
107 In total 334,976 participants of white British ancestry in UK Biobank were included in 
108 this study with an average age of 56 (standard deviation [SD]=8) years. A descriptive 
109 overview of selected UK Biobank study sample characteristics is given in Figure 1A. 
110 The UK Biobank participants are known to be more educated and healthier than the 
111 average UK population which is reflected in the high percentage of people with a 
112 university degree (47%) and low prevalence of current smoking (10%) in the sample, 
113 which is comparable to the full UK Biobank release (9). Furthermore, 34% of 
114 participants reported to have seen a general practitioner and 11% a psychiatrist for 
115 nerves, anxiety, tension or depression but there are few cases of schizophrenia 
116 (n=132), ADHD (n=71), ASD (n=143) or bipolar disorder (n=439). An overview of UK 
117 Biobank phenotype categories is given in Figure 1B.
118 DISORDER SPECIFIC EFFECTS
119 The MR-pheWAS of each psychiatric disorder tested the association of the respective 
120 polygenic risk score, aggregated from independent, genome-wide significant SNPs, 
121 with 23,004 outcomes in UK Biobank, adjusted for age, sex and the first 10 genetic 
122 principal components. There was strong evidence after multiple testing correction 
123 based on the number of independent tests derived from spectral decomposition 
124 (p<2.55x10-6) for associations of either the ADHD, ASD, SCZ, MDD or BP PRS with 
125 226 outcomes in 31 UK Biobank categories (Figure 2 and Table S1) as described 
126 below. A less stringent 5% FDR multiple testing threshold identified 209 additional 
127 outcomes also associated with at least one PRS (Figure S1). Correlations among the 
128 PRS can be found in supplementary Table S2. A detailed list of all MR-pheWAS results 
129 generated by the open-source PHESANT software package can be found in Table S3. 
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7130 Unless stated as a PHESANT result, estimates for continuous outcomes are 
131 generated by following up outcomes and manually curating the outcome phenotypes, 
132 to compute estimates on their original scale.
133 Attention deficit/ hyperactivity disorder
134 PRSADHD was strongly associated with 77 outcomes (Figure 3) including 39 socio-
135 demographic factors, 33 general health and 5 mental health, brain and cognition 
136 outcomes. The strongest evidence of association with PRSADHD was seen for socio-
137 demographic and lifestyle factors. A 1 SD higher PRSADHD was associated with a 
138 1.09 month younger age at first sexual intercourse [95% confidence interval [CI]: 
139 -1.26,-0.94] (p=2.0x10-16), and 0.96 lower odds of having a university degree [95% CI: 
140 0.95, 0.97] (p=1x10-29). In addition, PRSADHD was associated with younger maternal 
141 and paternal age of their parents (-0.08 years [95%CI: -0.103,-0.051] p=4.4x10-9; -0.10 
142 years [95% CI: -0.134,-0.067] p=3.2x10-9,respectively), 0.97 lower odds of average 
143 household income [95%CI: 0.96,0.97] (p=1.3x10-20), 1.05 higher odds of current 
144 smoking [95%CI :1.03,1.06] (p=5.7x10-15) and 1.04 higher odds of experiencing 
145 physical abuse as a child [95%CI: 1.02,1.06] (p=1.3x10-6).
146 Further, 1 SD increase in PRSADHD was associated with 17 physical health outcomes 
147 related to obesity, including 0.05 kg/m2 higher BMI [95%CI: 0.037,0.070] (p=7.4x10-11), 
148 leg and arm fat mass, waist circumference and trunk fat mass. Furthermore, there was 
149 evidence for an association of PRSADHD with blood measures, such as 0.02 cells/L 
150 higher leukocyte count [95%CI: 0.012,0.026] (p=1.4x10-7).
151 Associations seen for brain and cognition include 0.04 points lower fluid intelligence 
152 score [95%CI: -0.050,-0.026] (p=1.9x10-9).
153
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8154 Autism spectrum disorder
155 PRSASD was strongly associated with 9 outcomes (Figure 3), including 1 socio-
156 demographic, 7 general health and 1 mental health outcome.
157 The strongest association of PRSASD was found for lower erythrocyte distribution width 
158 where 1 SD higher PRSASD was associated with 0.01% lower erythrocyte distribution 
159 width [95% CI: -0.013, -0.007] (p=6.3x10-10) and 0.98 lower odds of comparative body 
160 size at age 10 [95%CI:0.97,0.98] (p=6.2x10-11). Furthermore, 1 SD higher PRSASD was 
161 associated with 0.001 g/cm2 lower heel bone mineral density (BMD) [95%CI:-0.002,-
162 0.001] (p=4.1x10-5).
163 The only mental health outcome that was associated with PRSASD was 1.02 higher 
164 odds of being a nervous person (“suffer from nerves”) [95%CI:1.01,1.03] (p=7.7x10-7).
165 Schizophrenia
166 There was strong evidence of association for PRSSCZ with 11 outcomes (Figure 3), 
167 including 2 socio-demographic, 4 mental health and cognition and 5 general health 
168 outcomes.
169 The strongest evidence of an association with PRSSCZ was detected for playing 
170 computer games (OR:0.98 [95%CI:0.976,0.989] p=1.4x10-7), 0.01% lower platelet 
171 distribution width [95%CI:0.003,0.006] (p=1.6x10-7) and having 0.68 lower odds of 
172 glioma cancer [95%CI:0.592,0.785] (p=1.2x10-7).
173 In addition, 1 SD increased PRSSCZ was associated with 0.42 sec longer duration of 
174 completing an online cognitive function test (alphanumeric path) [95%CI:0.237,0.580] 
175 (p=3.0x10-6) and a 19.1 mm3 reduced grey matter volume of the left putamen 
176 [95%CI:-26.9,-11.3] (p=1.5x10-6).
177
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9178 Major depressive disorder
179 PRSMDD was associated with 120 outcomes (Figure 3), including 18 socio-
180 demographic, 76 mental health and 26 general health outcomes.
181 Most of the associations (63%) were related to mental health, including an association 
182 of higher PRSMDD with higher odds of depression, anxiety, irritability, nervousness and 
183 mood swings. Strongest evidence of association with PRSMDD was found for 
184 1.07 higher odds of “seen a doctor for nerves, anxiety, tension or depression” 
185 [95%CI:1.066,1.081] (p=2.6x10-81), 0.11 points higher neuroticism score 
186 [95%CI:0.094,0.118] (p=2.0x10-16) and 1.05 higher odds of having mood swings 
187 [95%CI:1.045,1.060] (p=1.8x10-47).
188 Furthermore, there was strong evidence of 1 SD higher PRSMDD being associated with 
189 socio-demographic and lifestyle traits including 1.03 higher odds of ever smoking 
190 [95%CI:1.02,1.03] (p=8.4x10-14) and 1.04 higher odds of cannabis use 
191 [95%CI:1.03,1.06] (p=2.3x10-8).
192 Associated physical health measures included 0.97 lower odds of taking medication 
193 for pain relief, constipation or heartburn [95%CI:0.967,0.981] (p=4x10-6) and 1.02 odds 
194 of more frequent feelings of pain, e.g. back pain [95%CI:1.015,1031] (p=6x10-9).
195 Bipolar disorder
196 PRSBP was associated with 57 outcomes (Figure 3), including 19 socio-demographic, 
197 35 general health and 3 mental health outcomes.
198 Socio-demographic and lifestyle factors included associations of higher PRSBP with 
199 1.04 higher odds of having a university degree [95%CI:1.033,1.048] (p=4.5x10-26), 
200 0.02 hours/day less time spent watching television [95%CI:-0.027,-0.017] 
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201 (p=2.8x10-15) and lower average alcohol intake (OR:0.98 [95%CI:0.978,0.989] 
202 p=1.5x10-7).
203 General health traits included 19 traits indicating an association of 1 SD higher PRSBP 
204 with 0.07kg/m2 lower body weight and fat mass [95%CI:-0.090,-0.058] (p=2.0x10-16) 
205 and 5 traits related to blood measures, such as 0.004% decreased platelet distribution 
206 width [95%CI:-0.006,-0.003] (p=1.8x10-6).
207 The two traits related to mental health were risk taking (OR:1.03 [95%CI:1.018,1.035] 
208 p=2.9x10-19) and feeling fed-up (OR:0.98 [95%CI:0.975,0.989] p=2.5x10-7).
209 CROSS DISORDER CONSIDERATIONS
210 The highest overlap of associated outcomes of the univariable MR-pheWAS scans 
211 was seen for ADHD and BP with 11 socio-economic and lifestyle and 12 general health 
212 outcomes associated with both disorders (Figure 4). However, the majority of the 
213 associations are directionally opposite for ADHD and BP. For example, higher 
214 PRSADHD showed evidence for associations with lower educational attainment and 
215 higher BMI, whereas higher PRSBP was associated with higher educational attainment 
216 and lower BMI. Only a higher risk of smoking initiation (“ever smoked”) was 
217 directionally consistent for both PRSADHD and PRSBP.
218 Furthermore, all disorder PRSs showed some evidence for association with different 
219 blood cell counts, such as a decreased leukocyte count for PRSADHD and PRSMDD, or 
220 a decreased eosinophil count for PRSADHD and PRSSCZ.
221 There was very little overlap of highly associated outcomes between the 
222 neurodevelopmental domains (ADHD, ASD and SCZ).
223
224
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225 SENSITIVITY ANALYSIS
226 We repeated our tests of association of outcomes passing the spectral decomposition 
227 threshold, additionally adjusting for additional potential confounders (assessment 
228 centre, genotype chip and the first 40 principal components). Estimates were highly 
229 consistent with our main results, as shown in Table S4.
230 Relaxing the p-value threshold for including SNPs in the PRS resulted in some 
231 changes in the results (Figure S2). For ADHD, SCZ, MDD and BP the general trend 
232 was an inflation of p-values, with more associations below the significance threshold 
233 (Table S5) and higher effect estimates with smaller confidence intervals. A different 
234 pattern was observed for autism spectrum disorder with inconsistent results for some 
235 of the outcomes, as described in detail in the supplementary Text S1. Overall the 
236 strength of associations obtained for blood cell count traits across disorders varied 
237 between p-value thresholds, with weaker associations found for less stringent p-value 
238 thresholds.
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239 DISCUSSION
240 In this study, we conducted a MR-pheWAS to examine the relationships between 
241 genetic liability for five major psychiatric disorders and 23,004 outcomes in about 
242 300,000 UK Biobank participants.
243 Our results build on a large body of literature supporting links between genetic risk for 
244 psychiatric disorders with a wide variety of outcomes including psychological well-
245 being, lifestyle, socio-demographic factors and physical health (2, 4, 7, 10, 11). Our 
246 findings also suggest that although different psychiatric disorders show strong genetic 
247 overlap (7), genetic risk for distinct psychiatric disorders show differential associations 
248 with lifestyle, socio-demographic factors and physical health as highlighted in Figure 5. 
249 Genetic liability for ADHD and bipolar disorder showed the strongest associations with 
250 lifestyle and social environmental factors as well as physical health. On the other hand, 
251 genetic liability for major depression was most strongly associated with psychological 
252 health and associations with lifestyle and socio-demographic factors were less robust.
253 We were able to replicate previously reported associations between genetic liability 
254 for ADHD and lower educational attainment (12, 13), higher prevalence of smoking 
255 (14), younger age at delivery (15) and higher body mass index (16). While the previous 
256 findings for smoking and BMI were identified in young adults, our findings using an 
257 adult population-based sample with a mean age of 56 years, suggest that associations 
258 of childhood psychiatric disorder genetic liabilities with health and social outcomes 
259 persist into later adulthood. Associations of genetic liability for ADHD in childhood 
260 could represent effects of childhood ADHD or sub-threshold ADHD on long term social 
261 and economic outcomes, or alternatively associations could be due to parental effects 
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262 (due to their shared genetic risk of ADHD) or horizontal pleiotropy (the same genetic 
263 variants affecting multiple traits). 
264 Many of the associations of genetic liability for MDD with increased mood swings, 
265 irritability, feelings of loneliness and isolation are clinically known and have previously 
266 been reported (5). Our results are also in line with a recent publication from the 
267 Brainstorm consortium investigating genetic correlations among psychiatric disorders 
268 with neurological and quantitative traits using LD score regression and GWAS 
269 summary statistics, reporting high genetic correlations between most psychiatric 
270 disorders and educational attainment and BMI (2, 7). However, we found little 
271 evidence for associations of genetic liability for ADHD, ASD and schizophrenia with 
272 mental health outcomes, such as depressive symptoms, neuroticism or anxiety; and 
273 very few associations with cognitive or brain imaging outcomes, which might be 
274 because of the UK Biobank being a selected sample with lower rates of psychiatric 
275 disorders than the general population as discussed in the limitations section.
276 In addition to identifying previously reported associations of genetic liability for ASD, 
277 our MR-pheWAS also revealed novel associations. We found a strong association of 
278 genetic liability for ASD with decreased heel bone mineral density, which furthers 
279 previous evidence from observational studies that children and adolescents with ASD 
280 have lower bone mineral density (17, 18), higher frequency of bone fractures (19) and 
281 lower vitamin D levels (20, 21), which is essential for bone metabolism. This might 
282 suggest that these observed associations may be due to pleiotropic effects of genetic 
283 variants associated with bone health.
284 Our MR-pheWAS of schizophrenia suggested that genetic liability for schizophrenia 
285 was associated with lower grey matter volume in the left putamen and a lower risk for 
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286 glioblastoma cancer. Both phenotypes have been associated with schizophrenia in 
287 observational studies but it is not clear whether these phenotypes are determinants or 
288 consequences of schizophrenia, or due to confounding or shared genetic risk (22, 23). 
289 For glioblastoma our finding could be attributed to common underlying mechanisms 
290 that act in opposite directions, since it has been previously suggested that the same 
291 biological pathways leading to schizophrenia may be protective for developing 
292 glioblastoma (23). With respect to differences in brain volumes of schizophrenia 
293 patients, two large studies by the international ENIGMA (24) and Japanese COCORO 
294 (25) consortia found no notable difference in putamen volume between schizophrenia 
295 patients and controls or associations of brain volumes with a PRSSCZ in schizophrenia 
296 patients (26). Our results suggest that genetic risk for schizophrenia could be 
297 associated with putamen volume, but should be treated with caution because of 
298 potential selection bias due to the highly selected subset of about 10,000 UK biobank 
299 participants with brain scan data available at the time of data analysis (27). In line with 
300 our results, other previous work in schizophrenia patients and their relatives identified 
301 an association between schizophrenia and longer performance duration on the Trail 
302 Making Test (28), which requires searching and connecting irregularly arranged 
303 targets (digits and letters) in ascending order and is widely used to test for executive 
304 function, cognitive ability and processing speed (29-34).
305 Altered blood cell counts were associated with genetic liability for all disorders. Many 
306 psychiatric disorders previously have been associated with allergic or inflammatory 
307 states (35-37), such as asthma (38) and atopic diseases (39 , 40) but it is unclear 
308 whether high inflammatory states are on the causal pathway to disorder manifestation 
309 or the result of comorbid and confounding behaviours associated with the disease, 
310 such as restricted diet, overweight, risky behaviours or medication. Our results support 
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311 the possibility that altered blood cell counts could be a consequence of the disorder, 
312 but we cannot rule out contributions of horizontal pleiotropic effects. Also, considering 
313 the inconsistent findings from the sensitivity analyses for blood count traits, results 
314 need further validation and should be treated with caution.
315 Limitations
316 Patients with psychiatric disorders or high genetic liability for psychiatric disorders are 
317 known to be less likely to participate in studies in the first place and more likely to drop-
318 out during an ongoing study (41). Selection bias into a study as well as attrition can 
319 induce collider bias (42). There is consensus that the UK Biobank sample is not 
320 representative of the UK population, with participants showing, for example, lower 
321 prevalence of current smoking and lower rates of mortality (9). If both having a 
322 psychiatric disorder and a specific outcome (e.g. high socio-economic position) are 
323 associated with participation (the collider), this can induce an association between 
324 genetic risk for psychiatric disorders and the outcome, called collider bias. To reduce 
325 the possibility of collider bias we limited the set of included confounders in our main 
326 analysis but adjusted for assessment centre and genotype batch in sensitivity analysis.
327 A direct comparison of PHESANT estimates across the psychiatric disorders cannot 
328 be done without taking the differentially powered GWASs and derived PRS into 
329 account. This can also affect the number and set of outcomes associated with each 
330 disorder, which allows only a relative comparison among the outcomes. Further, the 
331 MDD GWAS used in the current study to calculate genetic risk scores included thirty 
332 thousand participants from UK Biobank (about 10% of the GWAS sample) which might 
333 have inflated our results for depression related items but is not expected to introduce 
334 bias in any other traits, such as blood counts. 
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335 Although genetic risk scores were derived using variants associated at genome-wide 
336 significance level, they can still have horizontal pleiotropic effects on different 
337 disorders and traits. Hence, our reported associations cannot on its own inform about 
338 causality but should be followed up with other causally informative methods. We 
339 therefore encourage triangulation of results using other study designs (43, 44), such 
340 as two-sample MR, negative control or twin studies. 
341 Conclusion
342 We were able to show that genetic liability for five common psychiatric disorders are 
343 associated with distinct aspects of adult life, including socio-demographic factors, 
344 mental and physical health. This is evident even in individuals from the general 
345 population who do not necessarily present with a psychiatric disorder diagnosis. 
346 However, there was surprisingly little overlap of findings for the different psychiatric 
347 disorder genetic risk scores despite the high genetic and symptomatic overlap of 
348 psychiatric disorders, such as schizophrenia and bipolar disorder. Furthermore, we 
349 want to emphasize the benefit of using genetic instruments for hypothesis-generating 
350 efforts in the field of psychiatry.
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351 METHODS
352 Study population
353 Between 2006-2010 UK Biobank recruited 503,325 men and women in the UK at ages 
354 40-69 years. The cohort contains a large dataset including physical measurements, 
355 blood/urine/saliva samples, health and lifestyle questionnaires as well as genotype 
356 (https://www.ukbiobank.ac.uk/).
357 For 463,010 participants genotyping was performed using the Affymetrix UK BiLEVE 
358 Axiom array or Affymetrix UK Biobank Axiom® array. Participants with non-white 
359 British ancestry (n=54,757) and 73,277 who have a kinship coefficient denoting a third-
360 degree relatedness were removed from an already quality checked dataset (excluding 
361 participants with withdrawn consent, sex mismatch or sex aneuploidy) (45), resulting 
362 in a dataset containing 334,976 participants (Figure 6).
363 UK Biobank received ethical approval from the research ethics committee (reference 
364 13/NW/0382). All participants provided informed consent to participate. This work was 
365 done under application number 16729 (using genetic data version 2 [500K with HRC 
366 imputation] and phenotype dataset 21753). 
367 Polygenic risk scores
368 Genetic variants were identified from the most recent GWAS summary statistics listed 
369 in Table 1 with p<5x10-8 for ADHD, ASD, SCZ, MDD and BP. This stringent p-value 
370 cut-off was chosen to minimize bias introduced by horizontal pleiotropic effects of 
371 genetic variants. All summary statistics were subject to standard quality control 
372 including filtering for minor allele frequency (MAF>0.1) and imputation quality 
373 (INFO>0.8) and excluding the MHC region on chromosome 6 (26-33Mb) due to its 
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374 complex linkage disequilibrium structure. Polygenic risk scores (PRS) were derived 
375 using PRSice v2.13 by identifying independent risk alleles in approximate linkage 
376 disequilibrium (R2<0.1 within 500kb distance) and computing a weighted, standardized 
377 mean score from these, as has been described previously (46).
378
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379 Table 1. Details of GWAS used for calculating PRS 
disorder cases controls SNPs in PRS1 Source
ADHD 20,183 35,191 10 Demontis et al. (2019) (2) 
ASD 18,381 27,969 2 Grove et al. (2017) (4)
Schizophrenia 36,989 113,075 113 Ripke et al. (2014) (3)
MDD 135,458 344,901 34 Wray et al. (2018) (5)
Bipolar disorder 20,129 21,524 8 Ruderfer et al. (2018)(47)
380 1- PRS derived from genome-wide significant hits (p<5x10-8)
381 2- SNP heritability estimates reported in the corresponding discovery sample
382 ADHD – Attention deficit/hyperactivity disorder, MDD – Major depression, ASD – Autism spectrum disorder
383 Outcomes
384 UK Biobank provides a fully searchable data showcase 
385 (http://biobank.ctsu.ox.ac.uk/crystal/ ) which at the time of data download (March 
386 2018) included 23,004 outcomes (see supplementary Text S2), including lifestyle and 
387 environment, socio-demographic, early life factors, anthropometry, family history and 
388 depression outcomes.
389 Age, sex and the first 10 principal components derived from the genetic data were 
390 included as covariates in all regression models. Age was derived from the participants 
391 date of birth and the date of their first assessment centre visit. Sex was self-reported 
392 and validated using genetic data.
393 PHESANT MR-pheWAS
394 PHESANT package (version 0.17) was used to test the association of each PRS with 
395 each outcome variable in Biobank. A detailed description of PHESANT’s automated 
396 rule-based method is given elsewhere (48, 49). In brief, decision rules are based on 
397 the variable field type and categorize each variable as one of four data types: 
398 continuous, ordered categorical, unordered categorical or binary. PHESANT then 
399 estimates the univariate association of the PRS (independent) with each outcome 
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400 variable (dependent) in a regression model, respectively. Normality of continuous data 
401 is ensured by an inverse normal rank transformation prior to testing. All estimates 
402 correspond to 1 SD change of the PRS. Selected continuous outcomes were followed 
403 up to compute meaningful estimates on the original phenotype scale for better 
404 interpretation.
405 PHESANT assigns each UK Biobank outcome to one of 91 level 3 categories based 
406 on the 235 origin categories of the UK Biobank catalogue (a full list of categories is 
407 provided in Table S1). Furthermore, three authors (BL, EW, ES) grouped these 91 
408 categories into four prespecified higher level categories in order to aid result 
409 presentation: socio-demographics and lifestyle, brain and cognition, mental health and 
410 general health (Figure 1B).
411 To account for multiple testing (n=23,004 tests) we used a previously derived threshold 
412 (49, 50) based on an estimate of the number of independent phenotypes calculated 
413 using spectral decomposition (phenoSPD) (n=19,645). The multiple testing adjusted 
414 significance threshold was p<2.55x10-6 (0.05/19,645). The amount of inflation of 
415 observed versus expected p-values is given as the ratio of the median chi-squared 
416 statistics for observed to expected median p-values, referred to as Lambda (λ). A 
417 conservative Bonferroni correction of multiple testing that assumes uncorrelated traits, 
418 would yield a similar p-value threshold of p<2.30x10-6 (0.05/23,004).
419 PHESANT sensitivity analysis
420 Analyses were re-run to assess residual confounding of assessment centre and 
421 genetic batch, including them as well as all 40 principal components as additional 
422 covariates for outcomes identified as strongly associated with either one of the 
423 disorders PRS. These covariates were not included in the first model because this 
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424 could introduce collider bias if, for example, location of assessment centre is affected 
425 by both genetic predisposition and outcomes, as discussed in the limitations section.
426 Furthermore, PRS were derived using various p-value thresholds (p<0.01, p <0.1x10-3, 
427 p<1x10-4, p<1x10-5, p<1x10-6) with consequently increasing numbers of SNPs (Table 
428 S6) and the five MR-pheWAS were re-run with the more relaxed PRS to capture a 
429 larger amount of explained variation in the disorders by accepting an increase in 
430 horizontal pleiotropic effects. For MDD GWAS results were available for only 10,000 
431 SNPs at these additional thresholds due to availability restrictions. 
432 All analyses were performed in R version 3.2.4 ATLAS and R version 3.3.1, and the 
433 code is available at [https://github.com/MRCIEU/Psychiatric-disorder-pheWAS-
434 UKBB]. Git tag v0.1 corresponds to the version presented here.
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598 Figures
599
600 Figure 1. Study overview. (A) Descriptive sample overview of selected outcomes in 
601 UK Biobank. (B) Categories of UK Biobank with the size of pie chart sections indicating 
602 the number of included outcomes: socio-demographics (n=2,057), general health 
603 (n=19,740), mental health (n=233), brain and cognition (n=974).
604 Figure 2. Overview of the distribution of disorder specific polygenic risk scores 
605 (p<5x10-8) associated outcomes per category of the UK Biobank variables catalogue. 
606 Shown are the number of associations with polygenic risk scores for attention 
607 deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), schizophrenia 
608 (SCZ), major depression (MDD) and bipolar disorder (BP).
609 Figure 3. MR-PheWAS results for attention deficit/hyperactivity disorder (ADHD), 
610 autism spectrum disorder (ASD), schizophrenia (SCZ), major depressive disorder 
611 (MDD) and bipolar disorder (BP). Left hand panel: QQ plots of expected versus 
612 observed p-values for association of PRS with all outcomes in UK Biobank. Red line 
613 indicates the significance threshold (2.5x10-6). Lambda (λ) indicates the degree of 
614 inflation from the expected fit. Right hand panel: selected results from different 
615 categories with p-values below the significance threshold and estimates generated by 
616 PHESANT. Results for continuous outcomes (std. β) are the standard deviation 
617 change of inverse-rank normal transformed outcome per 1 SD higher PRS.
618 Figure 4. Cross-disorder comparison. Shown are standardized log odds (upper 
619 section in each panel) or standardized beta-values (lower section of each panel) of all 
620 outcomes associated with polygenic risk scores for either attention deficit/hyperactivity 
621 disorder (ADHD), autism spectrum disorder (ASD), schizophrenia (SCZ), major 
622 depressive disorder (MDD) or bipolar disorder (BP) at p<2.55x10-6 as indicated by 
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623 stars (*). For outcomes categorized as ordered-logistic, only one outcome is displayed. 
624 Only associations with anthropometric measures of the right side of the body are 
625 shown. Estimates were generated by PHESANT. Results for continuous outcomes 
626 (std. beta) are the standard deviation change of inverse-rank normal transformed 
627 outcome per 1 SD higher PRS.
628 Figure 5. Categories of highly associated outcomes with polygenic risk scores for 
629 attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), 
630 schizophrenia (SCZ), major depressive disorder (MDD) and bipolar disorder (BP). Size 
631 of categories depends on the relative number of associated outcomes to the total 
632 number of outcomes within each category. Only categories with more than 1 variables 
633 are shown. Lifestyle and socio-demographic factors are shown in orange, physical 
634 health measures are shown in green and mental health, brain and cognition traits are 
635 shown in violet. Grey categories had zero hits for the corresponding disorder.
636 Figure 6. Overview of study sample derivation. Participants with withdrawn consent, 
637 sex mismatch or sex aneuploidy where already removed from the dataset in standard 
638 QC steps. (45)
639
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640 SUPPORTING INFORMATION
641
642 Figure S1. Overview of the distribution of disorder specific polygenic risk scores 
643 (p<5x10-8) associated outcomes per category of the UK Biobank variables catalogue 
644 after FDR adjustment for multiple testing. Shown are the number of associations with 
645 polygenic risk scores for attention deficit/hyperactivity disorder (ADHD), autism 
646 spectrum disorder (ASD), bipolar disorder (BP), major depressive disorder (MDD) and 
647 schizophrenia (SCZ).
648 Figure S2. Top associated outcomes with PRS for attention deficit/hyperactivity 
649 disorder (ADHD), autism spectrum disorder (ASD), schizophrenia (SCZ), bipolar 
650 disorder (BP) and major depressive disorder (MDD) across different p-value 
651 thresholds for SNP inclusion (5x10-8 – 1x10-2).
652 Table S1. Overview of UK Biobank categories with total number of outcomes per 
653 category and number of associated outcomes with polygenic risk scores passing the 
654 significance threshold (p<2.55x10-6). (ADHD- attention defict/ hyperactivity disorder, 
655 ASD- autism spectrum disorder, SCZ- schizophrenia, MDD- major depressive 
656 disorder, BP- bipolar disorder)
657 Table S2. Correlation matrix of polygenic risk scores (p<5x10-8). Correlation 
658 coefficients are displayed on the left side, p-values on the right side of the table. 
659 (ADHD- attention defict/ hyperactivity disorder, ASD- autism spectrum disorder, SCZ- 
660 schizophrenia, MDD- major depressive disorder, BP- bipolar disorder)
661 Table S3. MR-PheWAS results for association of generic risk of 5 common psychiatric 
662 disorders with 23,004 outcomes in UK Biobank. Genetic risk is defined as weighted 
663 sum of all genome-wide significant risk alleles for each disorder in 334,976 participants 
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664 of the UK Biobank. Estimates were generated by PHESANT. Results for continuous 
665 outcomes are the standard deviation change of inverse-rank normal transformed 
666 outcome per 1 SD higher PRS.
667 Table S4. MR-PheWAS follow-up and sensitivity results for selected continuous 
668 outcomes. Genetic risk is defined as weighted sum of all genome-wide significant risk 
669 alleles for each disorder in 334,976 participants of the UK Biobank. Estimates were 
670 generated by linear regression on the original variable scale per 1 SD higher PRS. 
671 Table S5. Number of strongly associated traits with PRS for attention-
672 deficit/hyperactivity disorder (ADHD), autism spectrum disorder 
673 (ASD),  schizophrenina (SCZ), major depressive disorder (MDD) and bipolar disorder 
674 (BP) at different p-value thresholds for PRS calculation.
675 Table S6. Number of SNPs included in polygenic risk scores for attention-
676 deficit/hyperactivity disorder (ADHD), autism spectrum disorder 
677 (ASD),  schizophrenina (SCZ), major depressive disorder (MDD) and bipolar disorder 
678 (BP) at different p-value thresholds.
679 Text S1. Sensitivity analysis for autism spectrum disorder
680 Text S2. UK Biobank outcomes description
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